The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy

Marc Stapley, CEO at Veracyte, joins OPTO Sessions to discuss the company’s use of AI and machine learning, its strategic focus on the cancer diagnostics cycle, and how its acquisition of MRD platform C2i expands this focus to the post-treatment phase.

#ai #machinelearningtraining #healthcareinnovation #cancertreatments #healthcareai #precisionmedicine